

MEDNAX, INC.  
Form 4  
February 13, 2017

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Goldschmidt, MD Pascal J

(Last) (First) (Middle)  
1301 CONCORD TERRACE  
(Street)  
SUNRISE, FL 33323

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
MEDNAX, INC. [MD]

3. Date of Earliest Transaction (Month/Day/Year)  
02/10/2017

4. If Amendment, Date Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|
|                                 |                                      |  | Code                           | V   | Amount  | (A) or (D)   | Price   |
| Common Stock                    | 02/10/2017                           |  | M                              |   | 818   | A  | \$ 32.325 14,173                                      |
| Common Stock                    | 02/10/2017                           |  | M                              |   | 10,668  | A  | \$ 27.715 24,841                                      |
| Common Stock                    | 02/10/2017                           |  | M                              |   | 9,922   | A  | \$ 29.355 34,763                                      |
| Common Stock                    | 02/10/2017                           |  | M                              |   | 8,280   | A  | \$ 36.25 43,043                                       |
| Common Stock                    | 02/10/2017                           |  | S                              |   | 25,294  | D  | \$ 67.8152 17,749                                     |
|                                 |                                      |  |                                |   |   |  | <u>(1)</u>  |

Edgar Filing: MEDNAX, INC. - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | Amount or Number of Shares |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|----------------------------|
| Stock Options (Right to Buy)               | \$ 32.325  | 02/10/2017                           |  | M                              | 818   | 11/01/2010 11/01/2017                                    | Common Stock  | 818                        |
| Stock Options (Right to Buy)               | \$ 27.715  | 02/10/2017                           |  | M                              | 10,668  | 05/23/2011 05/23/2018                                    | Common Stock  | 10,668                     |
| Stock Options (Right to Buy)               | \$ 29.355  | 02/10/2017                           |  | M                              | 9,922   | 05/06/2013 05/06/2020                                    | Common Stock  | 9,922                      |
| Stock Options (Right to Buy)               | \$ 36.25   | 02/10/2017                           |  | M                              | 8,280   | 05/05/2014 05/05/2021                                    | Common Stock  | 8,280                      |

## Reporting Owners

| Reporting Owner Name / Address  | Relationships |           |         |       |
|---|---------------|-----------|---------|-------|
|   | Director      | 10% Owner | Officer | Other |
| Goldschmidt, MD Pascal J<br>1301 CONCORD TERRACE<br>SUNRISE, FL 33323 | X             |           |         |       |

## Signatures

Dominic J. Andreano,  
Attorney-in-Fact

02/13/2017

\_\_\_\_\_\*Signature of Reporting Person

\_\_\_\_\_\*Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Sales of shares were made in thirty-three (33) separate transactions with prices ranging from \$67.70 to \$68.05 for an average weighted sales price of \$67.8152.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.